Pfizer starts construction on plant in Saudi Arabia; Lilly's Cymbalta tops DTC list;

@FiercePharma: Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article | Follow @FiercePharma

@EricPFierce: Must be some folks sorry Mylan got Agila and they didin't. Hikma says it is getting interest in its injectables biz. Story | Follow @EricPFierce

> Pfizer ($PFE) has started construction on its first manufacturing plant in Saudi Arabia. Story

> Questions arise over whether Roche ($RHHBY) will hit a wall with the price of its new breast cancer treatment Kadcyla. Story

> Eli Lilly's ($LLY) antidepressant Cymbalta still gets the most love in the DTC advertising race. Story

> Amarin ($AMRN) reported its earnings, saying that after a debt offering it has $260.2 million on hand. Release

> Merck ($MRK) CEO Kenneth C. Frazier says big risks are are essential to the company's future. Story

> There is renewed interest in orphan drugs now that incentives make their payouts larger. Story

Biotech News

 @FierceBiotech: From FierceBiotechIT.com : GSK jumps new IT hurdles in 'real-world' test of blockbuster hopeful. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Lundbeck gets EU nod for new drug to fight alcohol addiction--$300M tops; no U.S. plans. Story | Follow @JohnCFierce

@RyanMFierce: Alere grabbed some Gates Foundation funding for Tuberculosis and HIV testing products. Release | Follow @RyanMFierce

> As sequestration dawns, FDA supporters scramble to ease woes on drug reviews. Report

> Facebook, Google geeks 'hack' into cancer research problem with mobile game. More

> FDA pins approval on once-monthly version of blockbuster Abilify. Article

Medical Device News

 @FierceMedDev: Boston Scientific posts positive Watchman data. Item | Follow @FierceMedDev

 @MarkHFierce: Fledgling Dx company GeneCentric is raising money to support a lung cancer Dx commercial launch. More | Follow @MarkHFierce

 @DamianFierce: More worry for Intuitive Surgical as the FDA gets involved in the scrutiny of da Vinci robots. Story | Follow @DamianFierce

> Wright finalizes $190M-plus buy of BioMimetic. Story

> AtriCure 2012 losses, revenue grew as market push unfolded. Article

> Alere snags up to $42.2M from Gates Foundation for TB Dx. News

And Finally... Boehringer Ingelheim has picked República as its "cross-cultural advertising agency of record." Item

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.